Preferred Label : mucopolysaccharidosis I;
MeSH definition : Systemic lysosomal storage disease caused by a deficiency of alpha-L-iduronidase (IDURONIDASE)
and characterized by progressive physical deterioration with urinary excretion of
DERMATAN SULFATE and HEPARAN SULFATE. There are three recognized phenotypes representing
a spectrum of clinical severity from severe to mild: Hurler syndrome, Hurler-Scheie
syndrome and Scheie syndrome (formerly mucopolysaccharidosis V). Symptoms may include
DWARFISM; hepatosplenomegaly; thick, coarse facial features with low nasal bridge;
corneal clouding; cardiac complications; and noisy breathing.; A group of autosomal recessive lysosomal storage disorders caused by mutations in
the gene encoding the enzyme, alpha-L-iduronidase (IDUA), required for the degradation
of heparan and dermatan sulfates. This leads to abnormal accumulation of these glycosaminoglycans
in various tissues causing a wide range of clinical presentations including cognitive
and musculoskeletal disorders.;
MeSH synonym : lipochondrodystrophies; lipochondrodystrophy; mucopolysaccharidosis 1; mucopolysaccharidosis type I;
CISMeF synonym : Hurler; Scheie; type I, mucopolysaccharidosis; type is, mucopolysaccharidosis; deficiencies, alpha-L-Iduronidase; deficiency, alpha-L-Iduronidase; disease, hurler; hurlers disease; hurlers syndrome; mucopolysaccharidosis type Ih/S; mucopolysaccharidosis type Ih/Ss; pfaundler hurler syndrome; syndrome, Hurler-Scheie; syndrome, Pfaundler-Hurler; syndrome, hurler; syndrome, scheie; type Ih/S, mucopolysaccharidosis; type Ih/Ss, mucopolysaccharidosis; mucopolysaccharidosis IS;
MeSH hyponym : syndromes, scheie; scheie syndrome; Hurler-Scheie syndrome; Scheie's Syndrome; Syndrome, Scheie's; Mucopolysaccharidosis Type Is; Mucopolysaccharidosis I-S; Mucopolysaccharidosis I S; Mucopolysaccharidosis V; Mucopolysaccharidosis 5; Hurler Scheie Syndrome; Mucopolysaccharidosis Type Ih S;
CISMeF hyponym : mps i h s; mps i h-s; mps i-s; mps i s;
Related MeSH term : hurler syndrome; alpha-L-Iduronidase deficiency; Hurler's Disease; Disease, Hurler's; Hurler's Syndrome; Syndrome, Hurler's; Gargoylism; Gargoylisms; Gargoylism, Hurler Syndrome; Hurler Syndrome Gargoylism; Mucopolysaccharidosis Type Ih; Mucopolysaccharidosis Type Ihs; Type Ih, Mucopolysaccharidosis; Type Ihs, Mucopolysaccharidosis; Hurler Disease; Pfaundler-Hurler Syndrome; alpha L Iduronidase Deficiency; alpha-L-Iduronidase Deficiencies;
MeSH annotation : DF: MPS I;
Wikipedia link : https://en.wikipedia.org/wiki/Mucopolysaccharidosis i;
Related CISMeF synonym : mps i h;
Origin ID : D008059;
UMLS CUI : C0023786;
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
DO Cross reference
HPO term
Manual NTBT mappings (CISMeF)
ORDO relation(s)
Record concept(s)
See also
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
Validated automatic mappings to NTBT
Systemic lysosomal storage disease caused by a deficiency of alpha-L-iduronidase (IDURONIDASE)
and characterized by progressive physical deterioration with urinary excretion of
DERMATAN SULFATE and HEPARAN SULFATE. There are three recognized phenotypes representing
a spectrum of clinical severity from severe to mild: Hurler syndrome, Hurler-Scheie
syndrome and Scheie syndrome (formerly mucopolysaccharidosis V). Symptoms may include
DWARFISM; hepatosplenomegaly; thick, coarse facial features with low nasal bridge;
corneal clouding; cardiac complications; and noisy breathing.
A group of autosomal recessive lysosomal storage disorders caused by mutations in
the gene encoding the enzyme, alpha-L-iduronidase (IDUA), required for the degradation
of heparan and dermatan sulfates. This leads to abnormal accumulation of these glycosaminoglycans
in various tissues causing a wide range of clinical presentations including cognitive
and musculoskeletal disorders.
https://www.has-sante.fr/jcms/p_3312308/fr/aldurazyme-100-u/ml-laronidase
2022
false
false
false
France
insurance, health, reimbursement
enzyme replacement therapy
mucopolysaccharidosis I
hematopoietic stem cell transplantation
evaluation of the transparency committee
---
https://www.cochrane.org/fr/CD009354/lenzymotherapie-de-substitution-avec-laronidase-comme-traitement-pour-la-mucopolysaccharidose-de
2019
false
United Kingdom
France
French
review of literature
mucopolysaccharidosis I
treatment outcome
enzyme replacement therapy
french abstract
comparative study
iduronidase
---
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=FR&Expert=579
2011
true
France
French
English
Italian
mucopolysaccharidosis I
scientific and technical information
---
http://www.orpha.net/data/patho/Pub/fr/MucopolysaccharidoseType1-FRfrPub132v01.pdf
2010
France
French
mucopolysaccharidosis I
mucopolysaccharidosis I
mucopolysaccharidosis I
patient education handout
---
http://www.has-sante.fr/portail/display.jsp?id=c_569716
http://www.has-sante.fr/portail/display.jsp?id=c_569717
http://www.has-sante.fr/portail/display.jsp?id=c_569715
2007
France
French
watchful waiting
general practice
general practitioners
mucopolysaccharidosis I
mucopolysaccharidosis I
mass screening
prenatal diagnosis
genetic counseling
health education
health behavior
activities of daily living
continuity of patient care
rare diseases
chronic disease
interdisciplinary communication
hematopoietic stem cell transplantation
mucopolysaccharidosis I
iduronidase
patient care management
practice guideline
---